Bozic Carmen
SEC CIK 1790029 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| VRTX | Vertex Pharmaceuticals | EVP, CMO | 15.3K | — | $30.00M | 47 | 2022-02-01 | 2026-06-26 |
Most active insiders at VRTX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | LEIDEN JEFFREY M | Executive COB, Dir | — | $60.94M |
| 2 | Sachdev Amit | EVP Chief Patient, Ext Af Off | — | $28.38M |
| 3 | Kewalramani Reshma | CEO, Pres, Dir | — | $19.74M |
| 4 | Bozic Carmen | EVP, CMO | — | $11.31M |
| 5 | WAGNER CHARLES F JR | EVP, CO, FO | — | $10.78M |
| 6 | Tatsis Ourania | EVP, Chief Reg, Quality Off | — | $6.51M |
| 7 | McKechnie Duncan | EVP, Chief Commercial Off | — | $5.66M |
| 8 | Biller Jonathan | EVP, CLO | — | $4.08M |
| 9 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | — | $3.60M |
| 10 | Bunnage Mark E. | EVP, CSO | — | $3.00M |
Transactions 47
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-06-30 16:09 | 2026-06-26 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | S - Sale | $482.50 | -596 | 15.3K | -4% | -$287.6K |
| T | 2026-06-23 16:08 | 2026-06-18 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | S - Sale | $462.17 | -1,020 | 15.9K | -6% | -$471.4K |
| T | 2026-06-17 16:12 | 2026-06-15 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | S - Sale | $450.00 | -4,062 | 17.0K | -19% | -$1.83M |
| T | 2026-06-09 16:24 | 2026-06-05 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | S - Sale | $450.00 | -1,745 | 21.0K | -8% | -$785.2K |
| T | 2026-06-02 16:04 | 2026-05-29 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | S - Sale | $450.00 | -1,974 | 22.8K | -8% | -$888.3K |
| T | 2026-05-19 16:04 | 2026-05-15 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | S - Sale | $453.45 | -1,354 | 24.7K | -5% | -$614.0K |
| T | 2026-05-14 16:10 | 2026-05-12 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | S - Sale | $450.00 | -6,988 | 26.1K | -21% | -$3.14M |
| 2026-03-31 | 2026-03-27 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | S - Sale | $450.95 | -2,329 | 33.1K | -7% | -$1.05M | |
| 2026-03-17 | 2026-03-13 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | S - Sale | $481.79 | -2,329 | 35.4K | -6% | -$1.12M | |
| 2026-03-03 | 2026-02-27 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | S - Sale | $480.31 | -2,329 | 37.7K | -6% | -$1.12M | |
| 2026-02-26 | 2026-02-24 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | F - Tax | $485.11 | -1,453 | 40.1K | -3% | -$704.9K | |
| 2026-02-19 | 2026-02-17 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | A - Grant | $0.00 | +5,375 | 43.4K | +14% | $0 | |
| 2026-02-19 | 2026-02-17 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | F - Tax | $483.75 | -1,912 | 41.5K | -4% | -$924.9K | |
| 2026-02-18 | 2026-02-13 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | F - Tax | $487.76 | -3,804 | 38.1K | -9% | -$1.86M | |
| 2026-02-12 | 2026-02-10 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | F - Tax | $468.41 | -2,145 | 41.9K | -5% | -$1.00M | |
| M | 2026-01-26 | 2026-01-22 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | A - Grant | $0.00 | +11.3K | 44.0K | +35% | $0 |
| 2025-02-28 | 2025-02-26 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | F - Tax | $479.61 | -4,962 | 32.7K | -13% | -$2.38M | |
| 2025-02-26 | 2025-02-24 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | F - Tax | $483.28 | -3,310 | 37.6K | -8% | -$1.60M | |
| 2025-02-19 | 2025-02-14 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | F - Tax | $463.46 | -1,912 | 40.9K | -4% | -$886.1K | |
| 2025-02-14 | 2025-02-12 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | A - Grant | $0.00 | +5,546 | 42.9K | +15% | $0 | |
| 2025-02-12 | 2025-02-10 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | F - Tax | $467.98 | -2,142 | 37.3K | -5% | -$1.00M | |
| M | 2025-02-06 | 2025-02-04 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | A - Grant | $0.00 | +16.2K | 39.4K | +70% | $0 |
| 2024-08-08 | 2024-08-07 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | S - Sale | $476.75 | -2,280 | 23.3K | -9% | -$1.09M | |
| 2024-07-25 | 2024-07-24 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | S - Sale | $488.46 | -2,280 | 25.5K | -8% | -$1.11M | |
| 2024-07-12 | 2024-07-10 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | S - Sale | $487.34 | -2,280 | 27.8K | -8% | -$1.11M | |
| 2024-06-28 | 2024-06-26 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | S - Sale | $471.72 | -2,280 | 30.1K | -7% | -$1.08M | |
| 2024-06-13 | 2024-06-12 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | S - Sale | $478.00 | -2,280 | 32.4K | -7% | -$1.09M | |
| 2024-05-31 | 2024-05-29 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | S - Sale | $445.56 | -2,280 | 34.7K | -6% | -$1.02M | |
| 2024-02-27 | 2024-02-23 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | F - Tax | $431.79 | -3,309 | 36.9K | -8% | -$1.43M | |
| M | 2024-02-21 | 2024-02-16+ | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | F - Tax | $422.54 | -6,562 | 40.2K | -14% | -$2.77M |
| 2024-02-13 | 2024-02-09 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | F - Tax | $422.74 | -2,100 | 46.8K | -4% | -$887.8K | |
| M | 2024-02-08 | 2024-02-06+ | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | A - Grant | $0.00 | +19.6K | 48.9K | +67% | $0 |
| 2023-11-16 | 2023-11-14 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | S - Sale | $380.82 | -5,650 | 29.3K | -16% | -$2.15M | |
| 2023-11-02 | 2023-10-31 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | S - Sale | $355.92 | -5,651 | 35.0K | -14% | -$2.01M | |
| 2023-10-19 | 2023-10-17 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | S - Sale | $373.25 | -5,651 | 40.6K | -12% | -$2.11M | |
| 2023-10-05 | 2023-10-03 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | S - Sale | $345.28 | -5,651 | 46.3K | -11% | -$1.95M | |
| 2023-09-21 | 2023-09-19 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | S - Sale | $351.00 | -5,651 | 51.9K | -10% | -$1.98M | |
| 2023-09-07 | 2023-09-05 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | S - Sale | $352.66 | -5,651 | 57.6K | -9% | -$1.99M | |
| 2023-02-28 | 2023-02-24 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | F - Tax | $289.12 | -3,308 | 63.2K | -5% | -$956.4K | |
| 2023-02-22 | 2023-02-17 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | F - Tax | $292.85 | -3,750 | 66.5K | -5% | -$1.10M | |
| M | 2023-02-14 | 2023-02-10+ | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | F - Tax | $296.88 | -7,699 | 70.3K | -10% | -$2.29M |
| M | 2023-02-03 | 2023-02-01 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | A - Grant | $0.00 | +28.5K | 59.8K | +91% | $0 |
| 2022-06-02 | 2022-05-31 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | F - Tax | $271.24 | -311 | 49.5K | -0.6% | -$84.4K | |
| 2022-02-28 | 2022-02-24 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | F - Tax | $227.86 | -1,242 | 49.8K | -2% | -$283.0K | |
| 2022-02-22 | 2022-02-17 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | F - Tax | $232.51 | -3,439 | 51.1K | -6% | -$799.6K | |
| 2022-02-14 | 2022-02-10 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | F - Tax | $237.74 | -2,437 | 54.5K | -4% | -$579.4K | |
| M | 2022-02-03 | 2022-02-01 | VRTX | Vertex Pharmaceuticals | Bozic Carmen | EVP, CMO | A - Grant | $0.00 | +24.0K | 56.9K | +73% | $0 |
Purchase Sale Sale after option exercise All abbreviations